Pfizer has announced that Chief Financial Officer Dave Denton will step down and leave the pharmaceutical giant on August 15 to pursue a professional opportunity in the consumer goods sector.

 

The company has appointed Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer effective August 16 while Pfizer conducts a comprehensive search for a permanent successor. Denton and Guegan will work together to ensure a smooth leadership transition.

 

The departure marks a significant executive change for Pfizer as the company continues to execute its long-term growth strategy following a series of major acquisitions and portfolio investments.

 

“Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come. We wish him the very best as he returns to the consumer goods industry,” said Albert Bourla, Chairman and Chief Executive Officer. 

 

“Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organization and keep us focused on what matters most — executing our strategy and delivering for patients and shareholders."

 

Denton said he was leaving the company with confidence in its future leadership and direction.

 

“It has been an honor and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history,” said Dave Denton, Executive Vice President and Chief Financial Officer. “Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."

 

Guegan brings more than 20 years of experience at Pfizer and has held senior financial leadership roles across global operations, research and development, strategic portfolios, and multiple international markets.

 

In her current position, she oversees the financial operations and reporting of Pfizer’s global biopharmaceutical business across all therapeutic areas and geographic regions. She also played a key role in leading enterprise-wide initiatives, including the integration of Seagen into Pfizer in 2024.

 

Pfizer said Guegan’s extensive institutional knowledge, financial expertise, and leadership experience position her to guide the company’s finance organization during the transition period.

 

Guegan holds a Master in Business degree from Brest Business School.

 

The leadership change comes as Pfizer continues to focus on strengthening its portfolio, advancing innovation, and delivering long-term value for patients and shareholders.